Abstracts

Comparing the Development of a German Diabetes Population with Respect to Longterm Outcomes Using Data from the DETECT Study and the Eagle Diabetes Simulation Model

Mueller E, Walzer S, Pieper L, Klotsche J, Stridde E

1Analytica International, Loerrach, Germany, 2Technische Universität Dresden, Dresden, Germany, 3Pfizer Pharma GmbH, Karlsruhe, Germany

OBJECTIVES: Based on the type 2 diabetes cohort of the DETECT study (Curr Med Res and Opinion; 2005; 21/4: 619–29) simulations with the EAGLE Diabetes Model (Diab Technology & Therapeutics; 2006; 8/2: 219–36) were conducted. Development of long-term complications was compared with respect to different treatment targets for HbA1c. Additionally, the outcome for a mixed patient population typically for a general practice was assessed. METHODS: The Economic Assessment of Glycemic Control and Longterm Effects (EAGLE) model simulates long-term effects of diabetes treatment and related costs. Baseline characteristics of the simulation cohorts corresponded to type 2 patients of the DETECT study with HbA1c > 9%: age 63 ± 11 years, diabetes duration 9 ± 7 years, 49% male, hypertension prevalence 71%, mean HbA1c 10.1 ± 1.3%. Three cohorts with different HbA1c targets were defined: a) no change; b) 8%; and c) 6.4%. A fourth cohort was composed of 25% patients with target a) 60% target; b) and 15%; and target c). All cohorts achieve respective targets within one year followed by a yearly increase of 0.2%. Simulations were run with 1000 patients over 10 years. RESULTS: The relative risk reduction comparing cohort b versus no change was 19% (MI); 17% (stroke); 12% (PAD); 7% (prolif. retinopathy); and 4% (ESRD). A treatment target according to the German diabetes guideline (c versus a) resulted in reductions of 30%, 27%, 20%, 11%, and 6%, respectively. Analysing the mixed cohort demonstrated that treatment effects were similar to the results of cohort b. CONCLUSIONS: The simulations based on a German diabetes population demonstrate the long-term effects of various treatment targets for HbA1c. Although a steady re-increase of HbA1c values was assumed a significant reduction in micro- and macrovascular events can be achieved. Simulations of a mixed cohort correlate to real world patient groups and could be used for cost estimations in practice settings.

Drugs Use in Diabetic Patients

Cammarota S, De Portu S, Menditto E, Stefannini G, Mantovani LG

1University of Naples, Federico II, Naples, Italy, 2University of Naples, Federico II, Naples, Italy

OBJECTIVE: to assess the economic and epidemiologic impact of diabetes in Campania a region of approximately 5.7 million inhabitants in the south of Italy. METHODS: we collected, from an electronic database, all prescriptions for antidiabetic drugs reimbursed in the first half year of 2005 in 8 local health authorities (60% of the overall population) of Campania. The diabetic cohort was defined as the population of subjects receiving at least one prescription of an antidiabetic agent, classified according to their therapeutic role using Anatomic Therapeutic Chemical (ATC) classification. We identified 3 groups: who received only insulin (A) or only oral blood glucose lowering drugs (B) or both (C). Drugs cost and drugs consumption were quantified using NHS prospective (expressed in Euro 2005) and Defined Daily Dose system (DDD) respectively. RESULTS: The diabetic cohort included 200,070 subjects (5.7% of the observed population): 15.3% group A (mean age 62.7 ± 17.9 y.o., 0.78 M/F), 78.5% group B (mean age 65.7 ± 12.2 y.o., 0.85 M/F) and 6.2% group C (mean age 66.5 ± 11.1 y.o., 0.57 M/F). The mean drug/cost/patient was: 524.6€ group A (36.6% insulin, 27.1% cardiovascular drugs), 6290.4€ group B (11.1% oral hypoglycemic drugs, 47.1% cardiovascular drugs) and 6649.8€ group C (25.7% insulin, 5.4% oral hypoglycemic drugs, 34.6% cardiovascular drugs). Total cost for diabetic patients represents 17.8% of the total expenditures. CONCLUSION: Chronic-degenerative pathologies, such as diabetes, implies a relevant social and economic impact. Expenses that are associated to the treatment and the prevention of complications, in particular cardiovascular problems, are registered among the main items listed in the health care budget. Among diabetics patients the high use of drugs for cardiovascular problems is the cost driver.

Reimbursement of Pharmaceuticals and Brand-Generic Drug Utilization: Evidence from Oral Hypoglycemic Agents for Ambulatory Care in Taiwan

Liu YM, Kao Yang YH, Chen PC

National Cheng Kung University, Tainan, Taiwan

OBJECTIVE: This study is to investigate the impact of the National Health Insurance (NHI) reimbursement price on the utilization of brand name oral hypoglycemic agents (OHAs) and its generic counterparts for ambulatory care under an institutional context characterized by a health care system being lack of separating drug prescribing and dispensing as well as a hospital system with a large outpatient department, likely resulting in the monopsony power of hospitals over the wholesale market of pharmaceuticals. METHODS: Data is from the National Health Insurance Database 1997–2004 with 29,253 diabetic patient cohort data in 7 years. Patients’ severity is measured by the types of combination pharmacological therapy. The two-part model was used to estimate the effect of reimbursement price on
the choice and consumption of brand name and generic OHAs for each outpatient visit in the Defined Daily Dose. RESULTS: The regression results suggested a positive relationship between the reimbursement price and probability of prescribing brand name OHAs (odds ratio: 1.37, 95% CI: 1.36–1.37). The lower reimbursement price likely results in the lower consumption of both brand name (1.23; p < 0.01) and generic (0.93; p < 0.01) OHAs. The price elasticity of brand name OHAs is greater than that of generics OHAs. Large scale and private hospitals tend to prescribe generic OHAs, and those with higher accreditation level are inclined to prescribe brand name OHAs. CONCLUSION: The NHI price regulation generates the profit margin between reimbursement price and acquisition cost. Reducing the reimbursement price may squeeze the profit margin from brand name drugs, likely resulting in decreasing the probability of prescribing brand name drugs. The consumption of brand name drugs tends to be more sensitive to price adjustment than that of generic counterparts.

**PDB32**

**AMPUTATIONS IN DIABETIC FOOT ULCER PATIENTS USING NPWT**

Keith MS, Dhanda R, Boutton AJ

King’s College Hospital, London, UK

OBJECTIVES: This study aims to investigate the relative risk reduction (RRR) and number-needed-to-treat (NNT) estimates related to lower limb amputation events among patients with diabetic foot ulcer wounds using Negative Pressure Wound Therapy (V.A.C.® Therapy) compared to a similar patient population receiving other wound care treatments. METHODS: RRR and NNT estimates with NPWT in relation to an amputation event were evaluated using three distinct data sources. Two retrospective administrative databases of diabetic ulcer patients, including a commercial and a Medicare (CMS) population, as well as a RCT data for diabetic foot wound patients were evaluated. RRR and NNT for lower limb amputation events were calculated and compared between groups in each of the three populations. RESULTS: The commercial data yielded over 3500 patients, the Medicare data included over 12,700 patients, and the RCT included 162 patients. The RRR in amputation occurrence with NPWT vs. the control group was 34% for the commercial patient group and 35% for the Medicare patient group. The RRR was found to be even greater in the RCT group where NPWT was associated with over a 70% reduction in the risk of an amputation event. The NNT to prevent one amputation event with NPWT therapy was 14 for the commercial patient group, 18 for the Medicare patient group and 13 for the RCT group. Target NNTs in the range of 12–35 have been reported for preventing a subsequent adverse event. CONCLUSIONS: Using three different sources, this study is the first to evaluate the effectiveness of NPWT therapy by reporting calculated RRR and NNT related to lower limb amputations. The NNT to prevent an amputation event with NPWT therapy was consistent and low, ranging from 13 to 18. This data suggests that NPWT therapy is an effective intervention in reducing risk of amputation events in diabetic ulcer patients.

**PDB33**

**THE EFFICACY OF INSULIN GLARGINE COMPARED TO OTHER INJECTABLE THERAPIES—A META-ANALYSIS OF CLINICAL OUTCOMES IN INSULIN NAÏVE TYPE 2 DIABETES PATIENTS**

Pascoe K1, McDonald-Everett CM2, FitzGerald P3, Yurgin NR3, Seckin K2

1M-TAG Ltd, a unit of IMS, London, UK; 2Eli Lilly and Company, Indianapolis, IN, USA; 3formerly of M-TAG Limited, a unit of IMS, London, UK

OBJECTIVES: Achieving therapeutic goals in Type 2 diabetes often becomes more difficult as the disease progresses; many patients eventually require treatment beyond oral hypoglycaemic agents (OHA). The objective of this meta-analysis was to investigate which injectable therapies were either superior/inferior to bedtime-administered insulin glargine, (glargine) for key clinical outcomes. METHODS: A systematic review of all published glargine clinical trials (prior to October 2005) was conducted. Based on pre-defined inclusion criteria, the review encompassed all randomised controlled trials of at least eight-weeks duration that compared combination therapies (injectable therapy and OHA(s)), in insulin naïve patients. A random effects model was employed to incorporate the variability in between-study conditions. RESULTS: Seven trials met the specified criteria, with glargine chosen as the reference regimen. Although biphasic insulin aspart (BIA) and insulin lispro 75/25 were more efficacious than glargine at reducing HbA1c (in unadjusted (adjusted) analyses further reductions of −0.46 % (−0.41) and −0.39 % (−0.40) respectively were observed), this increase in efficacy was also associated with relative increases in the risk of experiencing hypoglycaemic events for both insulins and increased weight gain for BIA. Compared to glargine, exenatide and NPH were equally as efficacious at reducing HbA1c, although patients taking exenatide also benefited from weight reduction and a reduced risk of experiencing a nocturnal hypoglycaemic event. With respect to fasting blood glucose, exenatide, insulin lispro 75/25 and NPH were less efficacious than glargine. CONCLUSIONS: This meta-analysis found a slight increase in efficacy observed with the two twice-daily insulin regimens compared to glargine; however this result must be carefully balanced against the observed increase in adverse events, especially for patients where weight gain or hypoglycaemic events may be an issue. When glargine was compared to exenatide, similar HbA1c reduction was found but exenatide treated patients had fewer nocturnal hypoglycaemic events and experienced weight loss.

**PDB34**

**A POPULATION-BASED STUDY OF THE TIME TO INSULIN INITIATION/INTENSIFICATION AFTER FAILURE ON CURRENT THERAPY IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES IN THE UK**

Calvert MJ, Freemantle N, McManus RJ

University of Birmingham, Birmingham, UK

OBJECTIVE: To determine the time that patients with type 1 and type 2 diabetes remain on their existing therapy whilst uncontrolled, before starting insulin or intensifying their insulin regimen. METHODS: A retrospective cohort study was conducted among subjects with type 1 and type 2 diabetes. A total of 154 clinical practices with continuous data over a 10-year period from 1st May 1995 until 30th April 2005 were included in this analysis. The study identified 9979 individuals with type 1 diabetes (T1) and 62,533 individuals with type 2 diabetes (T2). Four patient groups were analysed: T1 on premix regimens; T2 prescribed ≥2 orals; T2 on basal regimen and T2 on premix regimens. The main study outcome was the median time to insulin...